drugset / Trial / NCT02312531
Prevention for Mother-to-infant Transmission of HBV
Non-randomizedParallel-groupOpen-labelPrevention
Summary
In this study, HBV-infected pregnant women were divided into two groups, those who received and those who did not receive hepatitis B immunoglobulin (HBIG) during pregnancy. In the mothers, the changes in HBV serum markers (hepatitis B surface antigen (HBsAg), hepatitis B surface antibody (HBsAb), HBeAg, hepatitis B core antibody (HBcAb)), and the DNA load were investigated. Immunohistochemical staining with custom-made antibodies against HBIG revealed both the level and distribution of HBIG in placentas. The protective mechanism of HBIG administrated during pregnancy was explored.
Timeline
- Start
- 2012-05
- Primary completion
- 2014-05
- Completion
- 2014-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Hepatitis B Immunoglobulin | Protein / enzyme biologic | 200 iu | — |